Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Receivables (2019 - 2025)

Pulmonx (LUNG) has disclosed Receivables for 7 consecutive years, with $13.8 million as the latest value for Q3 2025.

  • Quarterly Receivables rose 18.23% to $13.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $13.8 million through Sep 2025, up 18.23% year-over-year, with the annual reading at $13.1 million for FY2024, 8.38% up from the prior year.
  • Receivables for Q3 2025 was $13.8 million at Pulmonx, down from $15.9 million in the prior quarter.
  • The five-year high for Receivables was $15.9 million in Q2 2025, with the low at $5.1 million in Q1 2021.
  • Average Receivables over 5 years is $9.7 million, with a median of $8.9 million recorded in 2023.
  • The sharpest move saw Receivables skyrocketed 55.2% in 2021, then increased 4.36% in 2022.
  • Over 5 years, Receivables stood at $6.6 million in 2021, then skyrocketed by 32.23% to $8.7 million in 2022, then surged by 39.51% to $12.1 million in 2023, then grew by 8.38% to $13.1 million in 2024, then grew by 5.16% to $13.8 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $13.8 million, $15.9 million, and $14.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.